Connect with us

Press Releases

Aurion Biotech Raises $120 Million from Deerfield Management, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures

Deerfield Partner Andrew ElBardissi, M.D. and Petrichor Partner Patrick Lally to join Aurion Biotech board.

mm

Published

on

(PRESS RELEASE) SEATTLE & BOSTON & TOKYO — Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, announced it has secured a $120 million financing with top-tier biotech and ophthalmology investors. The financing was led by Deerfield Management, and included existing investors Petrichor Healthcare Capital Management, Flying L Partners, Falcon Vision, an ophthalmology-focused investment platform supported by KKR, and Visionary Ventures, a leading ophthalmology-focused venture fund creating value with better insight. Alcon also participated in the financing. Funds will be disbursed to the Company based on the achievement of key clinical and operational milestones.

Andrew ElBardissi, M.D. and partner at Deerfield Management, and Patrick Lally, partner at Petrichor, will join Aurion Biotech’s board of directors.

“We invest in experienced entrepreneurs, brilliant scientists and clinicians, and disruptive technologies that address significant unmet patient needs,” said Dr. ElBardissi. “We believe that Aurion Biotech possesses each of those key success factors and we look forward to supporting the Company’s next phase of growth and innovation.”

Aurion Biotech’s first candidate is a cell therapy for the treatment of corneal edema secondary to endothelial dysfunction, developed by world-renowned ophthalmic surgeon and research scientist Professor Shigeru Kinoshita and his colleagues at Kyoto Prefecture University of Medicine (KPUM) in Japan. The Company acquired this technology in 2020. Aurion Biotech is currently preparing to submit a J-NDA for market approval in Japan, and an IND to initiate clinical trials in the US.

Aurion Biotech intends to use the proceeds of this financing to advance its cell therapy program for corneal edema secondary to endothelial dysfunction, which affects approximately 16 million people in the US, Europe and Japan.

“Our financing speaks volumes about the potential of our cell therapy to transform the lives of millions of people suffering from corneal endothelial dystrophies,” said Greg Kunst, chief executive officer of Aurion Biotech. “We are inspired and gratified by the strategic support, insights and depth of resources our investors bring to Aurion Biotech – all of which will help to accelerate our momentum.”

Advertisement

Raymond James served as the exclusive financial advisor to Aurion Biotech, in connection with this offering.

SPONSORED VIDEO

Get the Practice of Your Dreams With Omg! Optical Marketing Group

This high volume practice had outgrown their ultra successful location and needed expansion. The idea was big, just like Texas! Design a fusion concept that featured optometry, aesthetics, fitness + wellness. Mission accomplished. Download the Free Lookbook.

Promoted Headlines

Advertisement

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Facebook

Most Popular